文献速递腹部泌尿生殖CTMR

2018版LI-RADS治疗反应算法对肝细胞癌患者层面阴性预测值的CT和MRI评估

Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
PubMed 文献 · Radiology · 2023-01-01

回顾性分析206例肝移植前接受CT或MRI评估的肝细胞癌患者,按LI-RADS治疗反应算法将患者分为有活性、不确定和无活性肿瘤,与移植病理对照。患者层面阴性预测值仅为32%(读者1)和26%(读者2),77%左右被判定为不确定的患者在移植病理上有残留肿瘤。

要点

  • 移植前按LI-RADS TRA判定为无活性肿瘤的患者,排除肝细胞癌的阴性预测值仅32%和26%。
  • 被判为不确定的患者中,75%(读者1)和77%(读者2)在移植病理上有残留肿瘤。
  • 读者间可靠性为中等至高度一致(加权κ=0.62)。

核心结论

  • 基于LI-RADS TRA的移植前CT或MRI患者层面分层,在排除移植病理证实的肝细胞癌方面阴性预测值低。

研究设计与样本

  • 单中心回顾性研究,纳入2011年1月至2017年11月连续218例接受肝移植的成人肝细胞癌患者,最终样本206例,以移植病理为参考标准,两名读者盲法评估移植前90天内CT或MRI。

诊断标准与关键数值

  • 患者层面判定:LR-4、LR-5或LR-TR有活性肿瘤归为有活性肿瘤;仅有LR-3或LR-TR不确定肿瘤归为不确定;仅有LR-TR无活性病灶归为无活性病变。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The Liver Imaging Reporting and Data System version 2018 (LI-RADS) treatment response algorithm (TRA) is a high-specificity, lower-sensitivity grading system to diagnose hepatocellular carcinoma (HCC) and recurrence after local-regional therapy. However, the emphasis on specificity can result in disease understaging, potentially leading to poorer posttransplant outcomes. Purpose To determine the negative predictive value (NPV) of pretransplant CT and MRI assessment for viable HCC on a per-patient basis using the LI-RADS TRA, considering explant pathology as the reference standard. Materials and Methods Patient records from 218 consecutive adult patients from a single institution with HCC who underwent liver transplant from January 2011 to November 2017 were retrospectively reviewed. Two readers blinded to the original report reviewed immediate (within 90 days) pretransplant imaging and characterized observations according to the LI-RADS TRA. Based on this, patients with LR-4, LR-5, or LR-TR (treatment response) viable tumors were designated as viable tumor; patients with solely LR-3 or LR-TR equivocal tumors were designated as equivocal; and patients with only LR-TR nonviable lesions were designated as no viable disease. Patients were designated as within or outside the Milan criteria. These per-patient designations were compared with the presence of viable disease at explant pathology. Fisher exact test was used to compare the differences between CT and MRI. Weighted κ values were used to calculate interreader reliability. Results Final study sample consisted of 206 patients (median age, 61 years [IQR, 57-65 years]; 157 male patients and 49 female patients). Per-patient LI-RADS TRA assessment of pretransplant imaging had an NPV of 32% (95% CI: 27, 38) and 26% (95% CI: 20, 33) (readers 1 and 2, respectively) for predicting viable disease. Seventy-five percent (reader 1) and 77% (reader 2) of patients deemed equivocal had residual tumors at explant pathology. Weighted interreader reliability was substantial (κ = 0.62). Conclusion Patient-based stratification of viable, equivocal, and nonviable disease at pretransplant CT or MRI, based on LI-RADS TRA, demonstrated low negative predictive value in excluding HCC at explant pathology. © RSNA, 2023 See also the editorial by Tamir and Tau in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Hassan OT, Behr SC, Ohliger MA, et al. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma. Radiology. 2023. PMID: 38112541. doi:10.1148/radiol.222776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。